A New Long Acting Liposomal Topical Antifungal Formula: Human Clinical Study
/ 0
- Details
- Category: Vol. 78, December 2010
- Hits: 870
A New Long Acting Liposomal Topical Antifungal Formula: Human Clinical Study,MOHAMED S. ABD EL-RHAMAN, WAEL SOLIMAN, FAWZIA HABIB and DINA FATHALLA
Abstract
Purpose: To study the clinical effect of topical controlled release ophthalmic fluconazole liposomal formulation on patients with candida keratitis.
Methods: This prospective uncontrolled study included 11 eyes of 11 patients with Candida Albicans keratitis (proved by cultures).
All were treated with topical liposomal fluconazole (2mg/ml) three times daily. The response to the treatment was divided into 3 categories: Complete improvement: Complete healing with scar formation at the end of one month, partial improvement: Decrease in the ulcer size at the end of one month and No improvement: Includes extension of ulcer size and or perforation which necessitates other approaches of management. The patients were examined daily over a 30- day period and results were recorded.
Results: Eleven eyes with candida albicans as proved with laboratory cultures were included in this study (7 males and 4 females). Three of the included patients in this study had diabetes mellitus and 2 patients had rheumatoid arthritis. Mean corneal ulcer diameter (mean of both horizontal and vertical diameters) was 5.5mm (ranges from 3.5 to 6.5mm). Mean duration of the ulcers at presentation was 7.6 days (ranges fro 3 to 14 days). Eight patients improved after 1 month while 1 patient had partial improvement and 2 patients did not improve and underwent amniotic membrane transplan-tation. One of the non improved patients progressed to perfo-ration and keratoplasty was done. Mean best corrected visual acuity was 1/60 which was not improved at the end the study.
Conclusion: Therapy with topical liposomal fluconazole (2mg/ml) carries high success rate and fast effect in treating patients with candida albicans keratitis.